Medical Cannabis - France

France

France is projected to reach a revenue of €163.30m in the Medical Cannabis market market by 2024.
The revenue is anticipated to experience a Compound Annual Growth Rate (CAGR 2024-2029) of 2.67%, leading to a market volume of €186.30m by 2029.
Among global counterparts, the United States is expected to generate the highest revenue of €13,470.00m in 2024.
In terms of per person revenues in 2024, €1.28k are generated in relation to the total population figures.
France's evolving regulatory framework is positioning it as a key player in the medical cannabis market, attracting investor interest and fostering industry growth.

Key regions: Australia, Europe, South Africa, United States, Netherlands

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The Medical Cannabis market in France has been experiencing significant growth and development in recent years.

Customer preferences: Customers in France are increasingly turning to medical cannabis products as an alternative form of treatment for various health conditions. The shift towards natural and holistic remedies has driven the demand for medical cannabis products among consumers who are seeking more personalized and effective healthcare solutions.

Trends in the market: One of the key trends in the French Medical Cannabis market is the growing acceptance and legalization of medical cannabis for therapeutic use. This shift in regulatory framework has opened up opportunities for both domestic and international companies to enter the market and offer a wide range of medical cannabis products to consumers. Additionally, there is a rising trend towards research and development in the field of medical cannabis, leading to the introduction of innovative products and treatment options.

Local special circumstances: France has a unique regulatory environment when it comes to medical cannabis, with strict regulations in place governing its production, distribution, and use. The country has been gradually expanding access to medical cannabis for patients with certain medical conditions, while ensuring that it is tightly controlled to prevent misuse and diversion. This balance between accessibility and regulation has created a challenging yet promising market landscape for companies operating in the medical cannabis sector.

Underlying macroeconomic factors: The development of the Medical Cannabis market in France is also influenced by broader macroeconomic factors such as changing consumer attitudes, healthcare policies, and economic conditions. As the healthcare industry continues to evolve and prioritize patient-centered care, medical cannabis is gaining recognition as a valuable therapeutic option. Moreover, the economic potential of the medical cannabis market is attracting investments and driving innovation in product development and distribution channels.

Methodology

Data coverage:

Data encompasses B2B and B2C enterprises. Figures are based on companies' revenues, funding values and global consumer survey data. Revenues include retail, sales and taxes.

Modeling approach / Market size:

Market sizes are determined by a Top-Down approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports, third-party data. Next, we use relevant key market indicators and data from country-specific associations such as tobacco spending per capita, medical product spending per capita, consumer spending and consumer spending for recreation purposes, population. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.